



ISHBT - Advocacy Team

Friday, 22th July, 2026

Delhi

The Indian Society of Haematology and Blood Transfusion (ISHBT) continues its dedicated advocacy efforts to strengthen and expand access to specialised haematology services across India. As part of this initiative, the ISHBT Advocacy Team held important discussions with Dr. Ranjan Choudhury, NHSRC, regarding key issues related to haematology healthcare delivery and policy. The team also met with Dr. Bijoy Deka, Deputy Commissioner, Medical (SST), Delhi, and discussed the inclusion of Haematology as a Super-speciality under the ESI Scheme for the management and treatment of haematological diseases, covering both benign and malignant disorders. Further, the ISHBT Advocacy Team engaged with the Office of the Drugs Controller General of India (DCGI) and its office bearers to discuss matters of importance to the haematology community and patients. These continued engagements reflect ISHBT's commitment to advocating for better recognition of the speciality, improved healthcare policies, wider access to specialised treatment, and stronger patient care pathways for individuals with haematological disorders. ISHBT remains committed to working with policymakers, regulatory authorities and healthcare institutions towards strengthening haematology services in India.

National Coagulation Conclave 2026

Friday & Saturday, 24th & 25th July, 2026

SGPGIMS, Lucknow

Lucknow, July 2026: The National Coagulation Conclave 2026, a two-day academic conference dedicated to advancing knowledge and clinical practice in coagulation and haemostasis, was held on 24th and 25th July 2026 at the Lecture Theatre Complex, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow.

Organised by the Department of Hematology, SGPGIMS, Lucknow, under the aegis of the Indian Society of Hematology and Blood Transfusion (ISHBT) and the Indian College of Hematology (ICH), the conclave will focus on the theme "Integrated Hemostasis: From Laboratory Insights to Clinical Practice."

The scientific programme will bring together eminent haematologists and experts from across the country to discuss recent advances and practical challenges in coagulation disorders. Key sessions will cover platelet disorders, haemophilia, inhibitors, non-factor therapies, gene therapy, von Willebrand disease, bleeding disorders in women, thrombophilia, lupus anticoagulant, TTP/HUS, acquired haemophilia,

paediatric and neonatal haemostasis, and laboratory coagulation. A special "Meet the Experts and Mentors" session will provide participants with an opportunity to discuss real-world clinical challenges and seek practical guidance from leading experts. The conclave will also feature oral presentations, a quiz, interactive panel discussions and case-based sessions.

The event is expected to provide an important platform for knowledge exchange, professional collaboration and strengthening integrated approaches to the diagnosis and management of bleeding and thrombotic disorders.



RAKTAVIGYAN

Saturday & Sunday, 22nd & 23rd August, 2026

Patna, Bihar

Patna, Bihar: The 8th Annual Conference of the Hematology Foundation of Bihar – RAKTAVIGYAN 2026 will be held on Saturday and Sunday, 22nd & 23rd August 2026, at Hotel Chanakya, Patna, Bihar. Organised by the Hematology Foundation of Bihar, in association with the Indian Society of Hematology & Blood Transfusion (ISHBT) and the Indian College of Hematology (ICH), the conference will bring together leading haematologists, clinicians, researchers and healthcare professionals from across the country. The theme of RAKTAVIGYAN 2026, "Bridging the Care Gap – Advancing Hematology to Rural & Urban India," highlights the need to make quality haematology services accessible to patients across all sections of society. The conference will feature scientific discussions and knowledge-sharing on contemporary advances in haematology, with special emphasis on thalassemia screening, prevention and comprehensive patient care. The programme will also promote public awareness regarding pre-marital thalassemia screening, carrier detection and the importance of informing doctors about thalassemia status before pregnancy.

With the message "एक कदम जागरूकता की ओर, एक कदम स्वस्थ भविष्य की ओर", RAKTAVIGYAN 2026 aims to strengthen awareness, collaboration and equitable haematology care while encouraging the spirit of voluntary blood donation.



Register Now - www.haematocon2026.in



SAVE THE DATE



29th - 30th
August 2026



Mayfair Waves
Puri, Odisha

Programme Director:
Prof. (Dr.) Rabindra Kumar Jena & Prof. (Dr.) Tuphan Kanti Dolai

Upcoming CMEs of ISHBT

HEMATO Conclave 2026

Organised by:
Indian Society of Haematology
and Blood Transfusion

Date: 29th - 30th August, 2026

Venue: Mayfair Waves, Puri, Odisha

Programme Director:
Prof. (Dr.) Rabindra Kumar Jena
& Prof. (Dr.) Tuphan Kanti Dolai

49TH MASTER CLASS

TOPIC
Emergency Room management of
Sickle Cell Disease



Dr. Ashutosh Panigrahi
MBBS, DNB
Fellow, American Society of Hematology

DATE
21ST AUGUST

TIME
07:00 PM IST

VENUE
The Regency
Puri, Odisha

Masterclass of ISHBT

49th Masterclass of ISHBT

Topic: Emergency Room management of
Sickle Cell Disease

Speaker: Dr. Ashutosh Panigrahi

Date: Wednesday, 19th August, 2026,

Time: 07:00 P.M. IST

<https://forms.gle/9NawGZMZVginWKR06>

Indian Journal of Haematology & Blood Transfusion (IJHBT)
Publishing model - Hybrid
Volume: 42, Issue: 4, July, 26
75 articles in this issue



Click below link to read or download
<https://link.springer.com/journal/12288/volumes-and-issues/42-4>

ISHBT Annual Circular 2026

Link to Download -
<https://ishbtish.com/imgs/circular/Annual%20Circular%202026.pdf>

ISHBT Election 2026 Circular

Link to Download -
<https://ishbtish.com/imgs/pdf/Election%20Circular%202026.pdf>

ISHBT Election 2026 - Nomination Form

Link to Download -
<https://ishbtish.com/imgs/pdf/Election%20Nomination%20Form%202026.pdf>

Guideline By Indian College of Hematology (ICH)



Available On

Jaypee Brothers Medical Publishers,
Amazon & AIBH

<https://ishbtish.com/ich/guidelines.html>

What's new in Haematology in June, 2026 in Myeloma & Lymphoma

Myeloma
Study: Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. Dimopoulos M, Schjesvold F, Fu C et al. The Lancet, 2026 Jun 14: S0140-6736(26)01088-3. doi: 10.1016/S0140-6736(26)01088-3
Interpretation
Mezigdomide–carfilzomib–dexamethasone provided a significant PFS benefit compared with carfilzomib–dexamethasone alone, with higher rates of grade 3 or 4 adverse events, including infections, which were mostly manageable with standard clinical practice and supportive care. These findings support mezigdomide–carfilzomib–dexamethasone as a clinically meaningful treatment option as early as first relapse in predominantly triple-class-exposed, anti-CD38 antibody-refractory and lenalidomide-refractory patients, a growing population with substantial unmet need.

THE LANCET
Study II: Talquetamab-Daratumumab in Relapsed or Refractory Myeloma. N Engl J Med. 2026 Jun 13. doi: 10.1056/NEJMoa2604657. Epub ahead of print. PMID: 42294841. Mina R, Beksac M, Rodríguez-Otero P, Chen W, Mateos MV et al.
Conclusions: Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, both Tal-DP (talquetamab plus daratumumab and pomalidomide) and Tal-D (talquetamab plus daratumumab) led to significantly longer progression-free survival than DPd (daratumumab plus pomalidomide and dexamethasone).

Lymphoma
Study I: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. Toby A Eyre, Yuqin Song, Olivier Hermine Et al. J Clin Oncol 2026 Jul 1: JCO2600550. doi: 10.1200/JCO-26-00550.
Conclusion: Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.

Journal of Clinical Oncology
Study II: Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis. Nicolas Gower, Pierre Feugier , Jason Westin et al. Blood 2026 Jun 18;147(25):3061-3068. doi: 10.1182/blood.2026033126.
In conclusion, the final analysis of RELEVANCE confirmed the absence of differences in efficacy outcomes between R2 and R-Chemo and the lack of new safety concerns, positioning R2 as a valid chemo-free alternative for patients with previously untreated, advanced FL. We believe these 10-year follow-up results constitute a benchmark for long-term expectations and comparisons with new promising chemo-free combinations currently tested in the front-line setting of FL.



+91 99030 35498



ishbtmail@gmail.com

Follow |





www.ishbtish.com